Please wait while the formulary information is being retrieved.
Drug overview for YERVOY (ipilimumab):
Generic name: IPILIMUMAB (IP-i-LIM-ue-mab)
Drug class: Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib
Therapeutic class: Antineoplastics
Ipilimumab, a recombinant, fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is an antineoplastic agent.
No enhanced Uses information available for this drug.
Generic name: IPILIMUMAB (IP-i-LIM-ue-mab)
Drug class: Antineoplastic-Cytotoxic T-Lymp. antigen (CTLA-4),R-MC Antib
Therapeutic class: Antineoplastics
Ipilimumab, a recombinant, fully human monoclonal antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), is an antineoplastic agent.
No enhanced Uses information available for this drug.
DRUG IMAGES
YERVOY 50 MG/10 ML VIAL
YERVOY 200 MG/40 ML VIAL
The following indications for YERVOY (ipilimumab) have been approved by the FDA:
Indications:
Adjuvant treatment of melanoma
EGFR negative, ALK negative, non-small cell lung cancer
Liver cell carcinoma
Malignant mesothelioma of pleura
Metastatic malignant melanoma
Microsatellite instability-high colorectal cancer
PD-L1 positive squamous cell carcinoma of esophagus
PD-L1 positive, EGFR-negative, ALK-negative metastatic non-small cell lung cancer
Renal cell carcinoma
Professional Synonyms:
Carcinoma of kidney
DMMR colorectal cancer
EGFR-negative, ALK mut (-) non-small cell lung cancer
EGFR-negative, ALK-negative, NSCLC
Grawitz tumor
Hepatocarcinoma
Hepatocellular carcinoma
Hypernephroid carcinoma
Hypernephroma
Kidney adenocarcinoma
Mismatch repair deficient colorectal cancer
MSI-H colorectal cancer
Nephroid carcinoma
PD-L1 expressing, EGFR mutation negative, ALK mutation negative metastatic NSCLC
PD-L1 positive esophageal squamous cell carcinoma
PD-L1 positive metastatic non-small cell lung cancer with no EGFR or ALK mutations
PD-L1 positive SCC of esophagus
PD-L1 positive, EGFR-negative, ALK-negative NSCLC
PD-L1+ SCC of esophagus
Renal adenocarcinoma
Renal carcinoma
Renal cell adenocarcinoma
Indications:
Adjuvant treatment of melanoma
EGFR negative, ALK negative, non-small cell lung cancer
Liver cell carcinoma
Malignant mesothelioma of pleura
Metastatic malignant melanoma
Microsatellite instability-high colorectal cancer
PD-L1 positive squamous cell carcinoma of esophagus
PD-L1 positive, EGFR-negative, ALK-negative metastatic non-small cell lung cancer
Renal cell carcinoma
Professional Synonyms:
Carcinoma of kidney
DMMR colorectal cancer
EGFR-negative, ALK mut (-) non-small cell lung cancer
EGFR-negative, ALK-negative, NSCLC
Grawitz tumor
Hepatocarcinoma
Hepatocellular carcinoma
Hypernephroid carcinoma
Hypernephroma
Kidney adenocarcinoma
Mismatch repair deficient colorectal cancer
MSI-H colorectal cancer
Nephroid carcinoma
PD-L1 expressing, EGFR mutation negative, ALK mutation negative metastatic NSCLC
PD-L1 positive esophageal squamous cell carcinoma
PD-L1 positive metastatic non-small cell lung cancer with no EGFR or ALK mutations
PD-L1 positive SCC of esophagus
PD-L1 positive, EGFR-negative, ALK-negative NSCLC
PD-L1+ SCC of esophagus
Renal adenocarcinoma
Renal carcinoma
Renal cell adenocarcinoma
The following dosing information is available for YERVOY (ipilimumab):
Dosage reduction is not recommended for adverse reactions. In general, withhold ipilimumab for severe (grade 3) immune-mediated adverse reactions.
Permanently discontinue ipilimumab therapy in patients experiencing life-threatening (grade 4) immune-mediated adverse reactions; recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment; persistent moderate (grade 2) or severe (grade 3) reactions (excluding endocrinopathy) lasting 12 weeks or longer after the last ipilimumab dose; or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids.
When ipilimumab is administered in combination with nivolumab, withhold or permanently discontinue both ipilimumab and nivolumab for toxicity.
Permanently discontinue ipilimumab therapy in patients experiencing life-threatening (grade 4) immune-mediated adverse reactions; recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment; persistent moderate (grade 2) or severe (grade 3) reactions (excluding endocrinopathy) lasting 12 weeks or longer after the last ipilimumab dose; or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids.
When ipilimumab is administered in combination with nivolumab, withhold or permanently discontinue both ipilimumab and nivolumab for toxicity.
Ipilimumab is available as a 5-mg/mL, preservative-free, injection concentrate in single-use vials containing 50 or 200 mg of the drug. Ipilimumab is administered by IV infusion. Dilution of the concentrate is required prior to administration.
Administer diluted ipilimumab through an IV line containing an inline, sterile, nonpyrogenic, low-protein-binding filter. Flush the IV line with 0.9% sodium chloride or 5% dextrose injection after each dose.
When administered in combination with nivolumab, infuse nivolumab first followed by ipilimumab on the same day. When administered with nivolumab and platinum-doublet chemotherapy, infuse nivolumab first followed by ipilimumab, and then platinum-doublet chemotherapy on the same day. Use separate infusion bags and filters for each infusion.
Do not co-administer other drugs through the same IV line. Store ipilimumab injection concentrate at 2-8degreesC. Do not shake or freeze; protect from light by storing in the original carton until time of use.
The diluted solution may be refrigerated (2-8degreesC) or stored at controlled room temperature (20-25degreesC) for no more than 24 hours from the time of preparation to the time of infusion. Discard any partially used vials, including unused diluted solution.
Administer diluted ipilimumab through an IV line containing an inline, sterile, nonpyrogenic, low-protein-binding filter. Flush the IV line with 0.9% sodium chloride or 5% dextrose injection after each dose.
When administered in combination with nivolumab, infuse nivolumab first followed by ipilimumab on the same day. When administered with nivolumab and platinum-doublet chemotherapy, infuse nivolumab first followed by ipilimumab, and then platinum-doublet chemotherapy on the same day. Use separate infusion bags and filters for each infusion.
Do not co-administer other drugs through the same IV line. Store ipilimumab injection concentrate at 2-8degreesC. Do not shake or freeze; protect from light by storing in the original carton until time of use.
The diluted solution may be refrigerated (2-8degreesC) or stored at controlled room temperature (20-25degreesC) for no more than 24 hours from the time of preparation to the time of infusion. Discard any partially used vials, including unused diluted solution.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| YERVOY 50 MG/10 ML VIAL | Maintenance | Adults infuse 3 mg/kg over 30 minute(s) by intravenous route every 3 weeks for 4 doses |
| YERVOY 200 MG/40 ML VIAL | Maintenance | Adults infuse 3 mg/kg over 30 minute(s) by intravenous route every 3 weeks for 4 doses |
No generic dosing information available.
The following drug interaction information is available for YERVOY (ipilimumab):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| IgG Antibodies and Derivatives/Efgartigimod-alfa SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3) CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3) DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3) |
VYVGART, VYVGART HYTRULO |
| IgG Antibodies and Derivatives/Nipocalimab-aahu SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3) CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3) DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3) |
IMAAVY |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| IgG Antibodies and Derivatives/Rozanolixizumab-noli SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3) CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3) DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3) |
RYSTIGGO |
| Immune Checkpoint Inhibitors/Proton Pump Inhibitors SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The mechanism of this interaction has not been fully investigated. Proposed mechanisms include: 1. Proton pump inhibitor (PPI)-induced changes of the microbiota (dysbiosis) causing resistance to immune checkpoint inhibitors, 2. Co-administration of PPIs with corticosteroids or non steroidal anti-inflammatory drugs (NSAIDs) and immune checkpoint inhibitors resulting in poorer prognosis.(1) CLINICAL EFFECTS: PPIs may decrease the therapeutic effects of immune checkpoint inhibitors. Several observational studies have shown a reduction in progression free survival (PFS), overall survival (OS), and tumor response in patients on concurrent treatment with immune checkpoint inhibitors and PPIs.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Concurrent use of immune checkpoint inhibitors and PPIs should be approached with caution. Manufacturers of immune checkpoint inhibitors do not provide recommendations on the concurrent use of PPIs. Primary literature on the concurrent use of these agents include recommendations to evaluate the risks and benefits of PPI use and consideration of alternative therapy when possible such as histamine H2-receptor antagonists (H2RAs) or antacids.(1-3) DISCUSSION: A meta analysis of 23 studies evaluating the impact of acid suppressing therapy on the efficacy of immune checkpoint inhibitors found coadministration of a PPI decreased PFS (HR 1.34 [95% confidence interval (CI), 1.13 to 1.58]) and OS (HR 1.43 [95% CI, 1.21 to 1.69]) compared with patients not treated with PPIs. Furthermore, the meta analysis identified that H2RAs did not affect OS. These results were consistent across cancer types.(1) In another meta analysis of 22 studies (5 prospective and 17 retrospective, n=16,072) evaluating the impact of concomitant medications on survival outcomes in patients treated with systemic therapy for advanced unresectable or metastatic renal cell carcinoma, concomitant use of PPIs (n=3959) was significantly associated with worse OS in patients treated with immune checkpoint inhibitors (HR 1.22, P=0.01).(4) A retrospective analysis of 635 patients treated with immune checkpoint inhibitors found PPI use was associated with significantly decreased OS (9 vs 26.5 months), PFS (3.5 vs. 8 months), and tumor response (61% vs. 72%).(5) Analysis of retrospective data from clinical trials of atezolizumab for urothelial carcinoma and non-small-cell lung cancer, among patients using a PPI within 30 days before or after therapy initiation, OS was significantly worse for patients randomized to treatment with atezolizumab than for patients randomized to chemotherapy.(6,7) A retrospective study of 381 patients treated with immune checkpoint inhibitors found use of acid-suppression therapy (n=168 PPIs, n=37 potassium competitive acid blocker, n=13 H2RAs) was associated with significantly shorter PFS and OS (2.9 vs. 6.2 months and 12.3 vs. 24 months, respectively) compared with patients who did not use acid-suppression therapy. However, when stratified by concomitant use of corticosteroids or NSAIDs, use of acid-suppression therapy was not associated with worse progression-free or overall survival.(8) In a retrospective cohort study of patients with advanced non-small-cell lung cancer treated with pembrolizumab, exposure to PPIs was associated with worse OS (HR, 1.13; 95% CI, 1.10-1.17).(9) Analysis of US and Japanese adverse drug event reporting system databases found administration of immune checkpoint inhibitors and PPIs was associated with an increased risk of adverse events including acute kidney injury (10) and congenital, familial and genetic disorders.(11) In a meta analysis of 14 observational studies, the risk of immune checkpoint inhibitor related AKI (ICI-AKI) in cancer patients concurrently using PPIs was found to be significantly higher (pooled OR of 1.84 [95% CI 1.16-2.90]) in comparison to the overall incidence of AKI from all-causes (1.57 [95% CI 1.02-2.40]).(12) In contrast to these findings, other studies have not found a negative effect on PFS or OS when patients are co-administered PPIs and immune checkpoint inhibitors. In a retrospective study of 159 patients treated with ipilimumab, coadministration of PPIs was associated with increased odds of experiencing a partial or complete response to ipilimumab (OR 3.73 [95% CI, 1.26 to 11.04]).(13) In another retrospective study of 233 patients who received nivolumab or pembrolizumab, use of PPI had no effect on OS (HR 1.2 [95% CI, 0.8-1.9]) or PFS (HR 1.1 [95% CI, 0.8 to 1.5]).(14) A nested case-control study of patients (n=38,930) with cancer who were new PPI or immune checkpoint inhibitor users and had no history of AKI before cohort entry, found the risk of AKI in patients treated with both PPIs and immune checkpoint inhibitors was not higher than then additional or multiplication of the risks in those who were treated with PPIs or immune checkpoint inhibitors alone. The study reinforces the association between PPIs and immune checkpoint inhibitors use and the increased risk of AKI and the need for careful monitoring and evaluation of kidney function when treated with both medicines.(15) |
ACIPHEX, ACIPHEX SPRINKLE, DEXILANT, DEXLANSOPRAZOLE DR, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM, KONVOMEP, LANSOPRAZOL-AMOXICIL-CLARITHRO, LANSOPRAZOLE, NAPROXEN-ESOMEPRAZOLE MAG, NEXIUM, OMECLAMOX-PAK, OMEPRAZOLE, OMEPRAZOLE-SODIUM BICARBONATE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM-0.9% NACL, PREVACID, PRILOSEC, PROTONIX, PROTONIX IV, RABEPRAZOLE SODIUM, TALICIA, VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, YOSPRALA |
The following contraindication information is available for YERVOY (ipilimumab):
Drug contraindication overview.
*None.
*None.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Lactation |
There are 3 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Guillain-barre syndrome |
| Myasthenia gravis |
| Pregnancy |
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hyperthyroidism |
| Hypothyroidism |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for YERVOY (ipilimumab):
Adverse reaction overview.
The most common adverse reactions (>=20%) with ipilimumab as a single agent are fatigue, diarrhea, pruritus, rash, nausea, and headache. The most common adverse reactions (>=20%) with ipilimumab in combination with nivolumab are fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, constipation, decreased weight, and dizziness. The most common adverse reactions (>=20%) with ipilimumab in combination with nivolumab and platinum doublet chemotherapy are fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus.
The most common adverse reactions (>=20%) with ipilimumab as a single agent are fatigue, diarrhea, pruritus, rash, nausea, and headache. The most common adverse reactions (>=20%) with ipilimumab in combination with nivolumab are fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, constipation, decreased weight, and dizziness. The most common adverse reactions (>=20%) with ipilimumab in combination with nivolumab and platinum doublet chemotherapy are fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus.
There are 68 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Colitis Lymphopenia |
Abnormal hepatic function tests Anemia Enterocolitis Hepatitis Hypercortisolism Hyperthyroidism Hypothyroidism Ileus Pituitary insufficiency |
| Rare/Very Rare |
|---|
|
Acute respiratory distress syndrome Adrenocortical insufficiency Aplastic anemia Autoimmune hemolytic anemia Autoimmune hepatitis Cytomegalovirus colitis DRESS syndrome Duodenitis Encephalitis Erythema multiforme Esophagitis Gastrointestinal perforation Gastrointestinal ulcer Giant cell arteritis Graft-versus-host disease Guillain-barre syndrome Hashimoto thyroiditis Hearing loss Hemophagocytic lymphohistiocytosis Hepatic failure Histiocytic necrotizing lymphadenitis Hypersensitivity angiitis Hypersensitivity drug reaction Hypersensitivity pneumonitis Hypophysitis Interstitial nephritis Interstitial pneumonitis Intestinal perforation Iritis Meningitis Multiple organ failure Muscle weakness Myasthenia gravis Myelitis Myocarditis Myositis Nephritis Orbital myositis Organ transplant rejection Pancreatitis Pericarditis Peripheral motor neuropathy Polymyalgia rheumatica Polymyositis Posterior reversible encephalopathy syndrome Renal failure Retinal detachment Rhabdomyolysis Sarcoidosis Scleritis Sepsis Stevens-johnson syndrome Toxic epidermal necrolysis Uveitis Vasculitis Vision impairment Vogt-koyanagi-harada disease |
There are 40 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Acute abdominal pain Anorexia Arthralgia Constipation Cough Diarrhea Dizziness Dyspnea Fatigue Fever Headache disorder Myalgia Nausea Pruritus of skin Skin rash Upper respiratory infection Weight loss |
Elevated serum amylase Elevated serum lipase Hypocalcemia Hypogonadotropic hypogonadism Hypokalemia Hyponatremia Increased alkaline phosphatase Insomnia Myopathy Pneumonia Skin inflammation Urticaria Vomiting |
| Rare/Very Rare |
|---|
|
Arthritis Blepharitis Blurred vision Conjunctivitis Eosinophilia Hypoesthesia Paresthesia Peripheral sensory neuropathy Psoriasis Reduced visual acuity |
The following precautions are available for YERVOY (ipilimumab):
The safety and effectiveness of ipilimumab have been established in pediatric patients 12 years of age and older for the following indications: as a single agent and in combination with nivolumab for unresectable or metastatic melanoma; in combination with nivolumab for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR ) unresectable and metastatic CRC; and in combination with nivolumab for MSI-H or dMMR mCRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. The safety and effectiveness of ipilimumab have not been established in pediatric patients <12 years of age with unresectable or metastatic melanoma or MSI-H or dMMR mCRC. The safety and effectiveness of ipilimumab have not been established in pediatric patients for the adjuvant treatment of melanoma or for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma, or esophageal cancer.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Based on findings from animal studies and its mechanism of action, ipilimumab can cause fetal harm when administered to a pregnant woman. There is insufficient human data for ipilimumab exposure in pregnant women. In animal reproduction studies, administration of ipilimumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in higher incidences of abortion, stillbirth, premature delivery (with corresponding lower birth weight), and higher incidences of infant mortality in a dose-related manner.
The effects of ipilimumab are likely to be greater during the second and third trimesters of pregnancy. Human IgG1is known to cross the placental barrier and ipilimumab is an IgG1; therefore, ipilimumab has the potential to be transmitted from the mother to the developing fetus. Verify pregnancy status in females of reproductive potential prior to initiating ipilimumab.
Advise pregnant women of the potential risk to a fetus. Report pregnancies to the manufacturer (Bristol-Myers Squibb) at 1-844-593-7869.
The effects of ipilimumab are likely to be greater during the second and third trimesters of pregnancy. Human IgG1is known to cross the placental barrier and ipilimumab is an IgG1; therefore, ipilimumab has the potential to be transmitted from the mother to the developing fetus. Verify pregnancy status in females of reproductive potential prior to initiating ipilimumab.
Advise pregnant women of the potential risk to a fetus. Report pregnancies to the manufacturer (Bristol-Myers Squibb) at 1-844-593-7869.
There are no data on the presence of ipilimumab in human milk or its effects on the breast-fed child or milk production. In monkeys, ipilimumab was present in milk. Because of the potential for serious adverse reactions in breastfed children, advise women not to breast-feed during treatment with ipilimumab and for 3 months following the last dose.
No overall differences in safety were observed between younger patients and patients >=65 years of age with ipilimumab as monotherapy for unresectable or metastatic melanoma or in combination with nivolumab for renal cell carcinoma. Although no overall differences in safety were observed between younger patients and patients >=65 years of age, discontinuation rates due to adverse reactions were higher in patients >=75 years of age who received combination treatment with ipilimumab and nivolumab for NSCLC, malignant pleural mesothelioma, metastatic CRC (in patients >=65 years of age), esophageal squamous cell carcinoma, and in patients who received ipilimumab in combination with nivolumab plus platinum-doublet chemotherapy.
The following prioritized warning is available for YERVOY (ipilimumab):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for YERVOY (ipilimumab)'s list of indications:
| Adjuvant treatment of melanoma | |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| EGFR negative, ALK negative, non-small cell lung cancer | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| Liver cell carcinoma | |
| C22.0 | Liver cell carcinoma |
| Malignant mesothelioma of pleura | |
| C45.0 | Mesothelioma of pleura |
| Metastatic malignant melanoma | |
| C43 | Malignant melanoma of skin |
| C43.0 | Malignant melanoma of lip |
| C43.1 | Malignant melanoma of eyelid, including canthus |
| C43.10 | Malignant melanoma of unspecified eyelid, including canthus |
| C43.11 | Malignant melanoma of right eyelid, including canthus |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.12 | Malignant melanoma of left eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C43.2 | Malignant melanoma of ear and external auricular canal |
| C43.20 | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21 | Malignant melanoma of right ear and external auricular canal |
| C43.22 | Malignant melanoma of left ear and external auricular canal |
| C43.3 | Malignant melanoma of other and unspecified parts of face |
| C43.30 | Malignant melanoma of unspecified part of face |
| C43.31 | Malignant melanoma of nose |
| C43.39 | Malignant melanoma of other parts of face |
| C43.4 | Malignant melanoma of scalp and neck |
| C43.5 | Malignant melanoma of trunk |
| C43.51 | Malignant melanoma of anal skin |
| C43.52 | Malignant melanoma of skin of breast |
| C43.59 | Malignant melanoma of other part of trunk |
| C43.6 | Malignant melanoma of upper limb, including shoulder |
| C43.60 | Malignant melanoma of unspecified upper limb, including shoulder |
| C43.61 | Malignant melanoma of right upper limb, including shoulder |
| C43.62 | Malignant melanoma of left upper limb, including shoulder |
| C43.7 | Malignant melanoma of lower limb, including hip |
| C43.70 | Malignant melanoma of unspecified lower limb, including hip |
| C43.71 | Malignant melanoma of right lower limb, including hip |
| C43.72 | Malignant melanoma of left lower limb, including hip |
| C43.8 | Malignant melanoma of overlapping sites of skin |
| C43.9 | Malignant melanoma of skin, unspecified |
| Microsatellite instability-high colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| Pd-l1 positive squamous cell carcinoma of esophagus | |
| C15 | Malignant neoplasm of esophagus |
| C15.3 | Malignant neoplasm of upper third of esophagus |
| C15.4 | Malignant neoplasm of middle third of esophagus |
| C15.5 | Malignant neoplasm of lower third of esophagus |
| C15.8 | Malignant neoplasm of overlapping sites of esophagus |
| C15.9 | Malignant neoplasm of esophagus, unspecified |
| Pd-l1 positive, EGFr-negative, ALk-negative metast NSCLC | |
| C34 | Malignant neoplasm of bronchus and lung |
| C34.0 | Malignant neoplasm of main bronchus |
| C34.00 | Malignant neoplasm of unspecified main bronchus |
| C34.01 | Malignant neoplasm of right main bronchus |
| C34.02 | Malignant neoplasm of left main bronchus |
| C34.1 | Malignant neoplasm of upper lobe, bronchus or lung |
| C34.10 | Malignant neoplasm of upper lobe, unspecified bronchus or lung |
| C34.11 | Malignant neoplasm of upper lobe, right bronchus or lung |
| C34.12 | Malignant neoplasm of upper lobe, left bronchus or lung |
| C34.2 | Malignant neoplasm of middle lobe, bronchus or lung |
| C34.3 | Malignant neoplasm of lower lobe, bronchus or lung |
| C34.30 | Malignant neoplasm of lower lobe, unspecified bronchus or lung |
| C34.31 | Malignant neoplasm of lower lobe, right bronchus or lung |
| C34.32 | Malignant neoplasm of lower lobe, left bronchus or lung |
| C34.8 | Malignant neoplasm of overlapping sites of bronchus and lung |
| C34.80 | Malignant neoplasm of overlapping sites of unspecified bronchus and lung |
| C34.81 | Malignant neoplasm of overlapping sites of right bronchus and lung |
| C34.82 | Malignant neoplasm of overlapping sites of left bronchus and lung |
| C34.9 | Malignant neoplasm of unspecified part of bronchus or lung |
| C34.90 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C34.91 | Malignant neoplasm of unspecified part of right bronchus or lung |
| C34.92 | Malignant neoplasm of unspecified part of left bronchus or lung |
| Renal cell carcinoma | |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
Formulary Reference Tool